Recurrence of angina pectoris after percutaneous coronary intervention is reduced by statins in Japanese patients

Journal of Cardiology

Volumn 58, Issue 3, 2011, Pages 208-215

  Tsunoda, Ryusuke ^a   Sakamoto, Tomohiro ^b   Kojima, Sunao ^c   Ogata, Yasuhiro ^a   Kitagwa, Akira ^d   Ogawa, Hisao ^c  

^a JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Clinical Trial Management Center   (Japan)

Author keywords

Cholesterol; New lesion; Restenosis; Secondary prevention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; RESTENOSIS; STABLE ANGINA PECTORIS; STROKE; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RECURRENCE; TREATMENT OUTCOME;

EID: 82855161371     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.07.002     Document Type: Article

References (22)

1. 4S Study Investigators Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995, 345:1274-1275.
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-2157.
4. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., Knudtson M., Dada M., Casperson P., Harris C.L., Chaitman B.R., Shaw L., Gosselin G., Nawaz S., Title L.M., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007, 356:1503-1516.
5. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B., Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention; a randomized controlled trial. JAMA 2002, 287:3215-3222.
6. Menotti A., Puddu P.E., Lanti M., Kromhout D., Blackburn H., Nissinen A. Twenty-five-year coronary mortality trends in the seven countries study using the accelerated failure time model. Eur J Epidemiol 2003, 18:113-122.
7. Sakamoto T., Kojima S., Ogawa H., Shimomura H., Kimura K., Ogata Y., Sakaino N., Kitagawa A., Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction (MUSASHI-AMI) Investigators Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006, 97:1165-1171.
8. Matsuzawa Y. Treatment by changing the life-style. Japan Atherosclerosis Society guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases 2002, Japan Atherosclerosis Society, Tokyo, pp. 24-6.
9. Chen M.S., John J.M., Chew D.P., Lee D.S., Ellis S.G., Bhatt D.L. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006, 151:1260-1264.
10. Nakamura M., Yamashita T., Yajima J., Oikawa Y., Ogasawara K., Sagara K., Koike A., Kirigaya H., Nagashima K., Otsuka T., Uejima T., Funada R., Matsuno S., Suzuki S., Sawada H., et al. Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. J Cardiol 2011, 57:172-180.
11. Zhang Z.J. Mortality benefit and reduced need for repeat revascularization with statin therapy among patients undergoing percutaneous coronary intervention. J Cardiol 2011, 57:360.
12. Gibson C.M., Pride Y.B., Hochberg C.P., Sloan S., Sabatine M.S., Cannon C.P., TIMI Study Group Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) substudy. J Am Coll Cardiol 2009, 54:2290-2295.
13. Yasue H., Mizuno Y., Harada E., Itoh T., Nakagawa H., Nakayama M., Ogawa H., Tayama S., Honda T., Hokimoto S., Ohshima S., Hokamura Y., Kugiyama K., Horie M., Yoshimura M., et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008, 51:1742-1748.
14. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E., The Cholesterol and Recurrent Events (CARE) Investigators Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100:230-235.
15. Salonen R., Nyssönen K., Porkkala-Sarataho E., Salonen J.T. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995, 76. 34C-9C.
16. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92:3172-3177.
17. Masumoto A., Hirooka Y., Hironaga K., Eshima K., Setoguchi S., Egashira K., Takeshita A. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001, 88:1291-1294.
18. Sakamoto K., Sakamoto T., Ogawa H., Kumamoto Joint Research on Hypercholesterolemia Investigators The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006, 28:1012-1021.
19. Sugiyama S., Fukushima H., Kugiyama K., Maruyoshi H., Kojima S., Funahashi T., Sakamoto T., Horibata Y., Watanabe K., Koga H., Sugamura K., Otsuka F., Shimomura I., Ogawa H. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-e51.
20. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
21. Nishigaki K., Yamazaki T., Kitabatake A., Yamaguchi T., Kanmatsuse K., Kodama I., Takekoshi N., Tomoike H., Hori M., Matsuzaki M., Takeshita A., Shimbo T., Fujiwara H., Japanese Stable Angina Pectoris Study Investigators Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: a randomized, comparative, multicenter study. JACC Cardiovasc Interv 2008, 1:469-479.
22. Matsuoka H., Kawakami H., Ohshita A., Kohno T., Shigemi S., Okayama H., Higaki J. Bare metal stent implantation for in-stent restenosis with a drug-eluting stent. J Cardiol 2010, 55:135-138.